Biomind Labs Inc. announced the completion of dose administration of 30 healthy subjects in the Company's Phase II trial of its novel drug candidate BMND01 for Treatment-Resistant Depression. 10% to 30% of people with depression exhibit treatment-resistant symptoms coupled with difficulties in social and occupational function, decline of physical health, poor quality of life, suicide ideation and attempts, self-injurious behavior, high relapse rate and increased health care utilization. The objectives of the trial are to establish the safety and tolerability of DMT.

In addition to evaluating side effects, thistrial will also allow Biomind to explore the origin of the observed side effects, given that different associated physiological, behavioral, and cognitive markers will be collected before, during, and after the trial.